MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Feasibility and Safety of Multisite Tissue and Biofluid Sampling for Alpha-Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4)

C. Linder, B. Mollenhauer, C. Coffey, T. Beach, T. Foroud, C. Adler, H. Riss, D. Ecklund, C. Caspell-Garcia, K. Dave, S. Deshpande, S. Lasch, V. Arnedo, L. Riley, C. Kopil, D. Jennings, L. Chahine (Philadelphia, PA, USA)

Meeting: 2017 International Congress

Abstract Number: 544

Keywords: Alpha-synuclein

Session Information

Date: Tuesday, June 6, 2017

Session Title: Parkinson's Disease: Pathophysiology

Session Time: 1:45pm-3:15pm

Location: Exhibit Hall C

Objective: The S4 study aims to characterize the distribution of alpha-synuclein (aSyn) pathology in multiple tissues and body fluids within the same Parkinson’s disease (PD) subjects and healthy controls (HC).  We herein report the feasibility and safety data from this study.

Background: PD is pathologically characterized by the presence of aSyn aggregates in the subcortical regions of the brain. Recent studies demonstrate that aSyn pathology is also abundant in peripherally innervated tissues, which could be a source of peripheral biomarker. Studies of both tissue and biofluids together in one and the same subjects have thus far used relatively small sample sizes, varied methodologies and have largely been from single centers. The S4 study evaluates aSyn species in multiple tissues and biofluids within the same subject at a single time point, with blinded evaluation by multiple experts.

Methods: S4 is a Michael J. Fox Foundation for Parkinson’s Research sponsored multi-center, cross-sectional, observational study evaluating aSyn pathology in multiple tissues and biofluids in individual subjects.  The enrollment of 60 PD subjects (20 early drug-naïve, 20 moderate without motor fluctuations, 20 advanced with motor fluctuations) and 20 HCs is on-going.  Clinical assessments include MDS-UPDRS, MOCA, UPSIT and dopamine transporter SPECT.  Biopsies of the skin, sigmoid colon submucosa, and submandibular gland are obtained. Biofluids collected include cerebrospinal fluid (CSF), saliva, and blood. Acquisition of all specimens occurs within 120 days of screening. Patients are contacted by telephone within 10 days of procedures for safety assessments.

Results: As of January 3, 2017, 6 sites have enrolled 13 HC and 46 PD (11 early, 19 moderate and 16 advanced stage) participants. 42 have completed all study procedures. 

Conclusions: Multisite tissue and biofluid sampling for aSyn is feasible and generally safe. 

To cite this abstract in AMA style:

C. Linder, B. Mollenhauer, C. Coffey, T. Beach, T. Foroud, C. Adler, H. Riss, D. Ecklund, C. Caspell-Garcia, K. Dave, S. Deshpande, S. Lasch, V. Arnedo, L. Riley, C. Kopil, D. Jennings, L. Chahine. Feasibility and Safety of Multisite Tissue and Biofluid Sampling for Alpha-Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4) [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/feasibility-and-safety-of-multisite-tissue-and-biofluid-sampling-for-alpha-synuclein-in-parkinsons-disease-the-systemic-synuclein-sampling-study-s4/. Accessed July 12, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/feasibility-and-safety-of-multisite-tissue-and-biofluid-sampling-for-alpha-synuclein-in-parkinsons-disease-the-systemic-synuclein-sampling-study-s4/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Screening and Treatment of Depression in Parkinson’s Disease within Movement Disorders Centers: A Quality Improvement Initiative
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley